This matters because it predicts what a related molecule should do.
I suspect the honest answer is that it depends, in which case I would like to know on what.
Assume I can obtain either option without difficulty, so availability is not the deciding factor.
What is the actual trade-off, and does it matter at the scale I am working at?
Start with the receptor combination, because glucagon plus GLP-1 and GIP plus GLP-1 are different drugs with different mechanisms despite the similar description.
The phase 2 MASH trial used biopsy-confirmed histological endpoints — improvement in steatohepatitis without worsening of fibrosis — and reported substantially higher response rates than placebo across the dose range.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
Placebo response in MASH histology trials is not small, so the between-arm difference rather than the active-arm rate is the number to read.
Phase 2 obesity results are published separately and should not be quoted as phase 3.
The MASH histology is the interesting result; the weight result is unremarkable in context.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant design tension is that the glucagon limb carries a glycaemic cost that the GLP-1 limb has to offset.
Glucagon receptor agonism drives hepatic fatty-acid oxidation and raises resting energy expenditure, which is a mechanistically different route to weight loss from appetite suppression and is why hepatic endpoints respond as they do.
Phase 2 obesity results reported mean weight reductions in the high teens over 46 weeks at the higher doses, which places it in the same region as the established dual agonists.
Current MASH endpoint definitions come from regulatory guidance requiring histological resolution without fibrosis worsening.
Research-use material is not approved for human use, and thin independent testing makes lot-level verification harder here than for the licensed molecules.
Phase 2. Label it as phase 2 whenever you cite it.
edited 1 Aug 2026 by Dr_Bram_Verhoeven — expanded the table to cover the lower concentration
Answering this needs the trial phase; the published histological results are phase 2 and the phase 3 programme is ongoing.
The glycaemic penalty from the glucagon limb constrains dosing in a diabetic population and is the reason the balance between limbs is a design parameter rather than a free choice.
Biopsy sampling variability puts a floor under precision in any histological trial, since two cores from one liver can differ by a fibrosis stage.
The caveat is that this is an investigational compound with no approved indication anywhere.
Read the between-arm difference, not the active-arm response rate.
Specifically, this is the compound where the hepatic mechanism is most directly evidenced, because the trial actually biopsied.
For research-grade material there is no reference standard in general circulation and very little published independent testing, so identity confirmation is the first problem rather than the last.
Glucagon receptor agonism raising energy expenditure is established from human infusion studies independent of any particular compound.
Glucagon plus GLP-1, not GIP plus GLP-1. The distinction is the compound.
edited 24 Jul 2026 by Dr_Idris_Coulibaly — removed a claim I could not source
The honest answer is that the phase 2 histology result is strong and that histology trials are small and biopsy reading is variable.
Fibrosis improvement was the more modest component of the histological result, which is the usual pattern: inflammation resolves before fibrosis regresses, if fibrosis regresses at all.
Glycaemia and heart rate are what the glucagon limb costs.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.